Analyzing R&D Budgets: Amicus Therapeutics, Inc. vs Dynavax Technologies Corporation

Biotech R&D: Amicus vs. Dynavax - A Decade of Change

__timestampAmicus Therapeutics, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 20144762400084580000
Thursday, January 1, 20157694300086943000
Friday, January 1, 201610479300084493000
Sunday, January 1, 201714931000064988000
Monday, January 1, 201827090200074951000
Tuesday, January 1, 201928637800062331000
Wednesday, January 1, 202030844300028607000
Friday, January 1, 202127204900032228000
Saturday, January 1, 202227667700046600000
Sunday, January 1, 202315238100054886000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting strategies in their R&D investments.

From 2014 to 2023, Amicus Therapeutics increased its R&D budget by over 220%, peaking in 2020 with a 547% rise from its 2014 spending. This surge underscores Amicus's aggressive pursuit of new therapies. In contrast, Dynavax Technologies saw a 35% decrease in R&D spending over the same period, reflecting a more conservative approach.

The data reveals a pivotal shift in 2018 when Amicus's R&D expenses surpassed Dynavax's by nearly 260%. This trend continued, highlighting Amicus's strategic focus on expanding its research capabilities. As the biotech landscape evolves, these spending patterns offer insights into each company's future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025